# A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis

> **NCT06850480** · PHASE3 · RECRUITING · sponsor: **Livzon Pharmaceutical Group Inc.** · enrollment: 356 (estimated)

## Conditions studied

- Reflux Esophagitis (RE)

## Interventions

- **DRUG:** JP-1366 simulation tablets
- **DRUG:** Esomeprazole Magnesium (Nexium) simulation tablets

## Key facts

- **NCT ID:** NCT06850480
- **Lead sponsor:** Livzon Pharmaceutical Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-05
- **Primary completion:** 2025-04-15
- **Final completion:** 2025-04-30
- **Target enrollment:** 356 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06850480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06850480, "A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06850480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*